Biomarker analysis from a phase I study using gedatolisib+palbociclib+hormone therapy in ER+/HER2- metastatic breast cancer (mBC).
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Pfizer (United States), University of Alabama at Birmingham, Moffitt Cancer Center, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Harvard University, Massachusetts General Hospital, The University of Texas MD Anderson Cancer Center, The Barbara Ann Karmanos Cancer Institute, University of Colorado Anschutz, University of Southern California, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Pfizer
OpenAlex ID: W3032229554